| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |